Journal
TRANSFUSION MEDICINE REVIEWS
Volume 35, Issue 3, Pages 36-43Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.tmrv.2021.06.002
Keywords
Antibodies; Monoclonal; CD38 antigen (p45) protein; plasma cells
Categories
Ask authors/readers for more resources
Daratumumab is a human monoclonal antibody targeting CD38 expressing-plasma cells, approved for the treatment of multiple myeloma and being investigated for other hematologic malignancies. It has potential applications in treating various antibody-mediated disorders beyond its current approved uses.
Daratumumab (DARA) is the biological name of an Immunoglobulin G1k human monoclonal antibody. DARA the first-in-class therapy targeting CD38 expressing-plasma cells (PC) and plasma blasts. It has been approved for the treatment of multiple myeloma. It is also being examined in the setting of other hematologic malignancies. As DARA targets PCs, it could potentially be used to treat many other disease processes that are antibody mediated. In fact, several case reports and case series report experiences of using DARA to treat a variety of antibody-mediated disorderss. The aim of this review is to present a summary of the literature thus far regarding the application of DARA beyond its uses in multiple myeloma and other hematologic diseases. Specifically, we address uses of DARA as an immunologic modulator in various antibody mediated processes. (c) 2021 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available